Navigation Links
Acquisitions, Clinical Trial Results, Date Extensions and Financial Results - Research Report on Endo, Astex, Auxilium, Accuray, and BioScrip
Date:9/2/2013

LEX Peyronie's program and are committed to working with the FDA while they complete their review. We are continuing to prepare for commercialization in Peyronie's disease, assuming FDA approval by the revised PDUFA date." According to the Company, the FDA has not requested for additional clinical studies to be performed prior to the revised PDUFA action date. The Full Research Report on Auxilium Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-28/AUXL]

--

Accuray Incorporated Research Report

On August 27, 2013, Accuray Incorporated (Accuray) reported its financial results for Q4 FY 2013 and full-year FY 2013 (period ended June 30, 2013). The Company's net revenue declined 15.6% YoY to $84.9 million during the quarter and dropped 22.8% YoY to $316 million for full-year FY 2013. Net loss attributable to stockholders was $18.7 million, or $0.25 per diluted share, in Q4 FY 2013, compared to net loss of $20.3 million, or $0.28 per diluted share, in Q4 FY 2012. For full-year FY 2013, net loss attributable to stockholders was $103.2 million, or $1.41 per diluted share, compared to net loss of $72.0 million, or $1.02 per diluted share, in full-year FY 2012. Commenting on the results, Joshua H. Levine, President and Chief Executive Officer of Accuray, said, "This was the second quarter in which we have shown growth and improvement in new order volume, driven by the actions we have taken to improve the commercial focus and execution of our business. I am encouraged that while we have seen improved commercial momentum, at the same time we have also reduced operating expenses, resulting in significantly lower operating losses and cash usage." The Full Research Report on Accuray Incorporated - including full detaile
'/>"/>

SOURCE Investors' Reports
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Verum.de Exhibits at Outsourcing in Clinical Trials Southern California
2. Leading the Site CTMS Market: Clinical Conductor CTMS Reaches 1,600 Sites
3. Clinovo Sponsors Outsourcing in Clinical Trials Southern California Conference 2013, in La Jolla (CA), September 24-25
4. Mytrus Electronic Informed Consent System Selected for 2013 Product Leadership Award in Clinical Trials
5. In Vitro Safety Screening for Clinical Liabilities, New Life Science Webinar hosted by Xtalks
6. ACRES Launches Global Clinical Research Network Technology Platform
7. Oncopeptides Initiates Phase II Clinical Study with Melflufen in the Treatment of Multiple Myeloma Patients
8. Indiana University Contracts with Virtify for Clinical Trial Disclosure Solutions
9. LabAnswer and OpGen Implement the STARLIMS Cloud Platform to Support OpGenā€™s CLIA Certified Clinical Services Laboratory in Under Four Months
10. Study Scavenger and CenterWatch Partner to Improve Patient Recruitment, Enrollment and Mobile Access to Clinical Trials with New Study Scavenger Smartphone App
11. MD Biosciences Offers IL-23-Induced Psoriasis-Like Preclinical Model for Skin Inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... TX (PRWEB) , ... July 29, 2015 , ... ... designer, manufacturer and supplier, announces the launch of their 2nd generation cell therapy ... the current miniPOD CT, but it also represents a new POD® design. ...
(Date:7/29/2015)... 2015  AmnioChor Inc., an early stage biotech startup ... to announce that the Musculoskeletal Transplant Foundation of ... in their seed round of development of the proprietary ... AmnioChor,s technology allows cryopreservation of the ... cells living within those tissues. Amnion is a well-established ...
(Date:7/29/2015)...  Indivior PLC (LON: INDV) today announced that the ... accepted and received Priority Review by the U.S. Food ... overdose. This naloxone nasal spray comes as a pre-filled ... into the nasal mucosa. 1 The device has ... be better equipped to help an opioid overdose victim. ...
(Date:7/29/2015)... QUEBEC CITY , July 29, 2015 /PRNewswire/ ... (the "Company") today announced it has selected an optimized ... important milestone in the development of a new ... The MAPK pathway represents a prime target for ... significant antitumor activities and survival benefits for B-Raf ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... Hyman Jr. Professor of Chemistry, was recently awarded ... the synthesis of a wide range of nanoscale ... of those materials, and the development of hierarchical ... the use of nanoscale materials in nanoelectronics, nanocomputing, ...
... Mich., Jan. 23, 2012  A recent Van Andel Research Institute ... the molecular structure and function of an essential plant hormone ... and might ultimately lead to the development of new drugs ... builds on earlier work by the same team of investigators ...
... 23, 2012 Aethlon Medical, Inc. ... filtration devices to address infectious disease, cancer and ... established an Extracorporeal Therapy Scientific Advisory Board to ... other therapies developed from the Aethlon ADAPT™ system.  ...
Cached Biology Technology:Van Andel Research Institute Study Provides New Details of Fundamental Cellular Process 2Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 2Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 3Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 4Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 5Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 6Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 7
(Date:7/2/2015)... DUBLIN , June 25, 2015 ... the addition of the "Next Generation Biometrics Market ... to 2020" report to their offering. ... $24.4 Billion by 2020, at a CAGR of 17.9% ... is the leading application for the market. Safran ...
(Date:6/30/2015)... -- To bolster its efforts and commitment to fighting cyber ... addition of two new team members. ... David Raviv will act as head of strategic alliances. ... providing the most secure solutions for the enterprise market. ... Technologies, a provider of security and management products, which was ...
(Date:6/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ... America Biomedical Sensors Market - Growth, Trends & Forecasts ... Latin America Biomedical Sensors market is estimated at $0.65 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Latin America Biomedical Sensors Market Report 2015-2020 2
... to diagnose infectious diseases are urgently needed in ... an American Academy of Microbiology colloquium, "Bringing the ... Resource Limited Settings," describes the challenges inherent in ... areas of the world where they are needed ...
... (SACRAMENTO, Calif.) A team of UC Davis investigators has ... in the development of prostate cancer. The mutation of the ... disease progression, but until now has never been shown to ... avenues for diagnosing and treating the disease. The ...
... As one of the few probiotics with medical food ... a collection of more than 80 studies that have demonstrated ... and an ileal pouch. Ulcerative colitis patients, in particular, have ... their prescription drug regimen. One particular study shows that the ...
Cached Biology News:Report addresses challenges in implementing new diagnostic tests where they are needed most 2UC Davis scientists find new role for P53 genetic mutation -- initiation of prostate cancer 2By adding VSL#3 probiotic to traditional therapies UC patients can improve remission rates 2
... The FailSafe™ PCR System is the ... the first time and every time. It ... regardless of the source or the property ... EPICENTRE's FailSafe™ PCR Enzyme Mix, a unique ...
...
... G|2 Doublestain System is a high-sensitivity ... kit. The kit is intended for ... detection of two different antigens within ... with suitably diluted rabbit and mouse ...
Anti-TNKS2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
Biology Products: